TECH
BuyPremium GrowerAI concernBio-Techne Corporation · Healthcare · United States · $11.4B
$72.40 +0.0% · close 2 Oct · scored 3 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Strong on the numbers, but the AI review named a specific concern. Its reason is in the AI review below.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Bio-Techne makes research reagents, antibodies, proteins and diagnostic tools and is a high-quality life-science business. Its shareholders have now approved an acquisition by Merck KGaA, Darmstadt, Germany. With a fixed takeover price agreed, the shares will trade toward that price until the deal closes, so the company's long-term growth no longer accrues to its current public shareholders beyond the offer.
ABOUT BIO-TECHNE CORPORATION
Read
Bio-Techne Corporation provides high-quality purified proteins, antibodies, immunoassays, and instrumentation essential for life science research and clinical diagnostics worldwide. The company's competitive moat is built on its deep scientific expertise and comprehensive portfolio of specialized reagents and instruments, fostering high customer loyalty among researchers and pharmaceutical firms. Bio-Techne is a key enabling partner in drug discovery, diagnostics, and cell & gene therapy development.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 1.2B | 1.2B | 3.3% | 1.2B | 1.3B | 1.4B | 4.7% |
| EPS | 1.73 | 1.81 | 1.07 | 0.47 | -35.3% | 1.16 | 0.49 | 0.56 | 6.2% |
| Shares | 156.6M | 157.6M | 158.2M | 155.0M | -1.1% | 156.8M | — | — | — |
| Debt | 326.0M | 455.0M | 419.5M | 444.1M | 10.9% | 289.1M | — | — | — |
| Equity | 1.7B | 2.0B | 2.1B | 1.9B | 4.1% | — | — | — | — |
| Op CF | 325.3M | 254.4M | 299.0M | 287.6M | -4.0% | 292.1M | — | — | — |
| Inv CF | -96.9M | -265.6M | -203.0M | -35.2M | — | — | — | — | — |
| Fin CF | -242.9M | 22.6M | -122.4M | -253.9M | — | — | — | — | — |
Swung more than 56% of stocks we rank over the past year (45% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TECH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TECH | Bio-Techne Corporation(you) | $11.4B | 70 | Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.0B | 66 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.1B | 74 | Buy |
| CORT | Corcept Therapeutics Incorporated | $12.2B | 75 | Buy |
| CAI | Caris Life Sciences, Inc. | $8.9B | 64 | Hold |
| LGND | Ligand Pharmaceuticals Incorporated | $5.9B | 73 | Buy |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.4B | 71 | Buy |
| TWST | Twist Bioscience Corporation | $10.5B | 47 | Hold |
| TGTX | TG Therapeutics, Inc. | $8.6B | 49 | Hold |
| HALO | Halozyme Therapeutics, Inc. | $12.8B | 94 | Strong Buy |
Peer medians: ROE -31.5% · P/E 25.1x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.